21
January 2025
VENTURE LIFE GROUP
PLC
("Venture
Life", "VLG" or the "Group")
Exercise of Share Options
& Total Voting Rights
Venture Life Group PLC (AIM: VLG), a
leader in developing, manufacturing and commercialising products
for the international self-care market, announces that it has
issued 1,000,000 ordinary shares of 0.3 pence each in the capital
of the Company ("Ordinary Shares") in accordance with an exercise
of share options, subject to admission to trading on
AIM.
Application will be made to the
London Stock Exchange for the 1,000,000 new Ordinary Shares to be
admitted to trading on AIM ("Admission") and it is expected that
Admission will become effective, and trading will commence at 8.00
a.m. on 24 January 2025.
Following Admission, the total
number of Ordinary Shares in issue will be 128,052,312 and the
total number of voting rights will therefore be 128,052,312. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company under the FCA's Disclosure and
Transparency Rules.
For
further information, please contact:
Venture Life Group PLC
+44 (0) 1344 578004
Jerry Randall, Chief Executive
Officer
Daniel Wells, Chief Financial
Officer
Cavendish Capital Markets Limited (Nomad and Broker)
+44 (0) 20
7720 0500
Stephen Keys/Camilla Hume (Corporate
Finance)
Michael Johnson
(Sales)
About Venture Life (www.venture-life.com)
Venture Life is an international
consumer self-care company focused on developing, manufacturing and
commercialising products for the global self-care market. With
operations in the UK, Italy, The Netherlands and Sweden, the
Group's product portfolio includes some key products such as the
UltraDEX and Dentyl oral care product ranges, the Balance Activ
range in the area of women's intimate healthcare, the Lift and
Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for
oncology support, Earol for ear wax removal, products for fungal
infections and proctology, and dermo-cosmetics for addressing the
signs of ageing. Its products are sold in over 90 countries
worldwide.
The products, which are typically
recommended by pharmacists or healthcare practitioners, are
available primarily through pharmacies and grocery multiples. In
the UK and The Netherlands these are supplied direct by the company
to retailers, elsewhere they are supplied by the Group's
international distribution partners.
Through its two Development &
Manufacturing operations in Italy and Sweden, the Group also
provides development and manufacturing services to companies in the
medical devices and cosmetic sectors.